Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Soft Tissue Sarcoma Patients

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer known as Soft Tissue Sarcoma. The study aims to explore the effectiveness of adding chemotherapy before and after surgery in patients with this cancer, who are considered high-risk based on a specific test called CINSARC. The chemotherapy treatment being tested includes medications such as Ifosfamide, Doxorubicin, and Dacarbazine Citrate. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein.

The purpose of the study is to determine if this additional chemotherapy can help prevent the cancer from spreading to other parts of the body, which is known as metastasis. Participants in the study will receive up to four cycles of chemotherapy, with each cycle lasting a few weeks. The study will compare the outcomes of patients receiving this treatment with those who receive the standard management for Soft Tissue Sarcoma.

Throughout the study, the health and progress of the participants will be closely monitored to assess the safety and effectiveness of the treatment. The main focus will be on how long patients remain free from metastasis, as well as their overall survival and any side effects experienced during the treatment. The study is expected to continue for several years to gather comprehensive data on the long-term benefits and risks of the chemotherapy regimen being tested.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, a diagnosis of soft tissue sarcoma must be confirmed. This involves a histological confirmation by a specialized network.

    Consent is required, and eligibility criteria must be met, including age, health insurance affiliation, and specific health conditions.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate health status. This includes blood tests to check blood cell counts, kidney and liver function, and heart function.

    A chest CT scan is performed to ensure the disease is localized and resectable.

  3. Step 3

    Treatment phase

    The treatment involves 4 cycles of chemotherapy using doxorubicin, ifosfamide, and dacarbazine. These medications are administered intravenously.

    Each cycle includes specific dosages and schedules, which are determined by the medical team based on individual health conditions.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to assess the response to treatment and manage any side effects. This includes periodic imaging and blood tests.

    Follow-up visits are scheduled to evaluate overall health and disease status, focusing on metastasis-free survival and disease-free survival.

  5. Step 5

    End of study

    The study is expected to conclude by February 2029. At this point, final assessments are made to determine the long-term outcomes of the treatment.

    The primary endpoint is to evaluate metastasis-free survival, while secondary endpoints include disease-free survival and overall survival.

Who can join the trial?

16 criteria

  • Must have a confirmed diagnosis of soft tissue sarcoma, which is a type of cancer that occurs in the soft tissues of the body.
  • Must have a high-risk CINSARC signature, which is a specific genetic marker used to assess the risk level of the cancer.
  • Must have acceptable hematologic function, meaning the blood cells are within a certain range: Absolute neutrophil count (ANC) of at least 1.5 G/L, platelet count of at least 100 G/L, and hemoglobin greater than 9g/dL.
  • Must have acceptable renal function, meaning the kidneys are working well: Serum creatinine should be 1.5 times the normal limit or less, or creatinine clearance should be at least 60 mL/min.
  • Must have acceptable liver function, meaning the liver is working well: Bilirubin should be 1.5 times the normal limit or less, and AST (SGOT) and ALT (SGPT) should be 2.5 times the normal limit or less.
  • Must have a normal LVEF (left ventricular ejection fraction) of more than 50%, which measures how well the heart is pumping blood.
  • Tumors must be graded as 1, 2, or 3 according to the FNCLCC grading system, which is a way to classify the severity of the cancer.
  • The disease must be resectable and localized, meaning it can be surgically removed and has not spread, confirmed by a chest-CT scan.
  • There should be 6 weeks or less between surgical removal of the tumor and joining the study, if surgery was done before joining.
  • Must have an available archived FFPE tumor sample, which is a preserved sample of the tumor tissue, in enough quantity for testing.
  • Must be 18 years of age or older.
  • Must have an ECOG performance status of 2 or less, which is a scale that measures the ability to perform daily activities.
  • Must have a life expectancy of at least 12 weeks after starting the treatment.
  • Women must be post-menopausal or agree to use effective birth control during treatment and for a specified time after treatment ends. Non-menopausal women must have a negative pregnancy test before joining. Men must agree to use effective birth control during treatment and for at least 3 months after treatment ends.
  • Must have signed a written informed consent, agreeing to participate in the study.
  • Must be affiliated with a Social Health Insurance in France.

Who cannot join the trial?

4 criteria

  • Patients who do not have a diagnosis of Soft Tissue Sarcoma cannot participate. Soft Tissue Sarcoma is a type of cancer that starts in the soft tissues of the body, like muscles or fat.
  • Patients who are not considered high-risk according to CINSARC cannot participate. CINSARC is a tool used by doctors to assess the risk level of certain cancers.
  • Patients who are younger than 4 years old or older than 18 years old cannot participate.
  • Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups like pregnant women or people who cannot make decisions for themselves.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Doxorubicin is a chemotherapy medication used in this trial. It is part of the treatment plan to see if it can help improve the chances of survival without the cancer spreading in patients with high-risk soft tissue sarcoma. The study is testing whether adding this medication before and after surgery can be more effective than the usual treatment approach.

What is already known about the treatment

Doxorubicin – Doxorubicin is administered intravenously, typically as part of a chemotherapy regimen. It is currently well-established in medical literature as a treatment for various cancers, including soft tissue sarcoma. The main therapeutic indication for doxorubicin in this context is to improve metastasis-free survival in patients with high-risk localized soft tissue sarcoma. At the molecular level, doxorubicin works by intercalating DNA strands, thereby inhibiting the replication of cancer cells. It is classified as an anthracycline antibiotic in pharmacology.

Investigated diseases

Soft Tissue Sarcoma – Soft Tissue Sarcoma is a type of cancer that begins in the soft tissues of the body, such as muscles, fat, blood vessels, nerves, tendons, and the lining of joints. It can occur in any part of the body but is most commonly found in the arms, legs, and abdomen. The disease often starts as a painless lump or swelling, which may grow over time. As it progresses, it can invade nearby tissues and organs, potentially leading to pain or other symptoms depending on its location. The growth rate and behavior of the tumor can vary significantly, with some types growing slowly and others more rapidly. The risk of metastasis, or spread to other parts of the body, is a concern, particularly in high-risk cases.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515384-62-00Protocol code19SARC05Estimated enrolment600 patientsSponsorOncopole Claudius Regaud

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).